A Phase 1 interventional study of OPC-41061 in Healthy Adult Male, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-28.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To assess the bioequivalence of OPC-41061 OD tablets and OPC-41061 conventional tablets at 15 and 30 mg in healthy adult male subjects.
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OPC41061 (15 mg) orally disintegrating tablet is administered with water.
Drug: OPC-41061
OPC41061 (15 mg) orally disintegrating tablet is administered without water.
Drug: OPC-41061
OPC-41061 (15 mg) conventional tablet is administered with water.
Drug: OPC-41061
OPC41061 (30 mg) orally disintegrating tablet is administered with water.
Drug: OPC-41061
OPC41061 (30 mg) orally disintegrating tablet is administered without water.
Drug: OPC-41061
OPC-41061 (30 mg) conventional tablet is administered with water.
Drug: OPC-41061
Maximum Plasma Concentration (Cmax) of Tolvaptan
Blood sampling for plasma tolvaptan concentration before IMP administration and 1, 2, 3, 4, 5, 6, 8, 10, 12, and 16 hours postdose in each period in Cohort 1 and 2 was performed for pharmacokinetic evaluation.
Time frame: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours post-dose
Area Under the Concentration-time Curve From Time Zero to the Last Observable Concentration at Time t (AUCt) of of Tolvaptan
Blood sampling for plasma tolvaptan concentration before IMP administration and 1, 2, 3, 4, 5, 6, 8, 10, 12, and 16 hours postdose in each period in Cohort 1 and 2 was performed for pharmacokinetic evaluation.
Time frame: Pre-dose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours post-dose
This single-center, open-label, randomized, 3-period 3-way, crossover study using 2 different formulations and 2 different dosing regimens investigated bioequivalence between tolvaptan orally disintegrating (OD) and conventional tablets in 84 healthy adult male subjects in 2 cohorts. Bioequivalence between the OD and conventional 15 mg tablets was investigated in Cohort 1. In Cohort 2, bioequivalence between the OD and conventional 30 mg tablets was investigated.
| Milestone | Cohort 1: Conventional Tablet, Then OD Tablet Without Water, Then OD Tablet With Water | Cohort 1: OD Tablet With Water, Then Conventional Tablet, Then OD Tablet Without Water | Cohort 1: OD Tablet Without Water, Then OD Tablet With Water, Then Conventional Tablet | Cohort 2: Conventional Tablet, Then OD Tablet Without Water, Then OD Tablet With Water | Cohort 2: OD Tablet With Water, Then Conventional Tablet, Then OD Tablet Without Water | Cohort 2: OD Tablet Without Water, Then OD Tablet With Water, Then Conventional Tablet |
|---|---|---|---|---|---|---|
| Started | 14 | 14 | 14 | 14 | 14 | 14 |
| Completed | 14 | 14 | 13 | 14 | 14 | 14 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Cohort 1: Conventional Tablet, Then OD Tablet Without Water, Then OD Tablet With Water | Cohort 1: OD Tablet With Water, Then Conventional Tablet, Then OD Tablet Without Water | Cohort 1: OD Tablet Without Water, Then OD Tablet With Water, Then Conventional Tablet | Cohort 2: Conventional Tablet, Then OD Tablet Without Water, Then OD Tablet With Water | Cohort 2: OD Tablet With Water, Then Conventional Tablet, Then OD Tablet Without Water | Cohort 2: OD Tablet Without Water, Then OD Tablet With Water, Then Conventional Tablet |
|---|---|---|---|---|---|---|
| Started | 14 | 14 | 13 | 14 | 14 | 14 |
| Completed | 14 | 13 | 13 | 14 | 13 | 14 |
| Not completed | 0 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 1 | 0 |
| Milestone | Cohort 1: Conventional Tablet, Then OD Tablet Without Water, Then OD Tablet With Water | Cohort 1: OD Tablet With Water, Then Conventional Tablet, Then OD Tablet Without Water | Cohort 1: OD Tablet Without Water, Then OD Tablet With Water, Then Conventional Tablet | Cohort 2: Conventional Tablet, Then OD Tablet Without Water, Then OD Tablet With Water | Cohort 2: OD Tablet With Water, Then Conventional Tablet, Then OD Tablet Without Water | Cohort 2: OD Tablet Without Water, Then OD Tablet With Water, Then Conventional Tablet |
|---|---|---|---|---|---|---|
| Started | 14 | 13 | 13 | 14 | 13 | 14 |
| Completed | 14 | 13 | 13 | 14 | 13 | 14 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Blood sampling for plasma tolvaptan concentration before IMP administration and 1, 2, 3, 4, 5, 6, 8, 10, 12, and 16 hours postdose in each period in Cohort 1 and 2 was performed for pharmacokinetic evaluation.
| ng/mL | Cohort 1: 15 mg Conventional Tablet | Cohort 1: 15 mg OD Tablet Without Water | Cohort 1: 15 mg OD Tablet With Water | Cohort 2: 30 mg Conventional Tablet | Cohort 2: 30 mg OD Tablet Without Water | Cohort 2: 30 mg OD Tablet With Water |
|---|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Tolvaptan | 131 ± 71.0 | 149 ± 72.6 | 125 ± 63.1 | 203 ± 72.7 | 218 ± 56.0 | 198 ± 54.7 |
Blood sampling for plasma tolvaptan concentration before IMP administration and 1, 2, 3, 4, 5, 6, 8, 10, 12, and 16 hours postdose in each period in Cohort 1 and 2 was performed for pharmacokinetic evaluation.
| ng*h/mL | Cohort 1: 15 mg Conventional Tablet | Cohort 1: 15 mg OD Tablet Without Water | Cohort 1: 15 mg OD Tablet With Water | Cohort 2: 30 mg Conventional Tablet | Cohort 2: 30 mg OD Tablet Without Water | Cohort 2: 30 mg OD Tablet With Water |
|---|---|---|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero to the Last Observable Concentration at Time t (AUCt) of of Tolvaptan | 697 ± 440 | 674 ± 361 | 685 ± 392 | 1120 ± 334 | 1130 ± 306 | 1110 ± 312 |
Collected over Treatment-emergent adverse events were collected during the treatment period (8 days). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: 15 mg Conventional Tablet | 0/41 (0%) | 0/41 (0%) | 1/41 (2.4%) |
| Cohort 1: 15 mg OD Tablet Without Water | 0/41 (0%) | 0/41 (0%) | 1/41 (2.4%) |
| Cohort 1: 15 mg OD Tablet With Water | 0/41 (0%) | 0/41 (0%) | 2/41 (4.9%) |
| Cohort 2: 30 mg Conventional Tablet | 0/42 (0%) | 0/42 (0%) | 1/42 (2.4%) |
| Cohort 2: 30 mg OD Tablet Without Water | 0/42 (0%) | 0/42 (0%) | 0/42 (0%) |
| Cohort 2: 30 mg OD Tablet With Water | 0/41 (0%) | 0/41 (0%) | 0/41 (0%) |
| Event | Cohort 1: 15 mg Conventional Tablet | Cohort 1: 15 mg OD Tablet Without Water | Cohort 1: 15 mg OD Tablet With Water | Cohort 2: 30 mg Conventional Tablet | Cohort 2: 30 mg OD Tablet Without Water | Cohort 2: 30 mg OD Tablet With Water |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/41 | 1/41 | 0/41 | 0/42 | 0/42 | 0/41 |
| VomitingGastrointestinal disorders | 0/41 | 0/41 | 1/41 | 0/42 | 0/42 | 0/41 |
| Alanine Aminotransferase IncreasedInvestigations | 1/41 | 0/41 | 1/41 | 1/42 | 0/42 | 0/41 |
Safety analysis set: all subjects that received at least 1 dose of investigational medicinal product (IMP).
| Age, Continuous(years) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Mean | 24.4 ± 4.3 | 23.5 ± 4.8 | 24.0 ± 4.5 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 42 | 42 | 84 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Japanese | 42 | 42 | 84 |
| Region of Enrollment(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Japan | 42 | 42 | 84 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in Feb 2017, 1 month.
Results were first posted in Jun 2021, 4 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tolvaptan
Otsuka Pharmaceutical Co., Ltd. →